Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Effects of Omeprazole on Plasma Levels of RaltegravirIWAMOTO, Arian; WENNING, Larissa A; AZROLAN, Neal et al.Clinical infectious diseases. 2009, Vol 48, Num 4, pp 489-492, issn 1058-4838, 4 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapySAAH, Alfred J; HAAS, David W; CONDRA, Jon H et al.The Journal of infectious diseases. 2003, Vol 187, Num 7, pp 1157-1162, issn 0022-1899, 6 p.Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteersSAAH, Alfred J; WINCHELL, Gregory A; NESSLY, Michael L et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 10, pp 2710-2715, issn 0066-4804Article